Yale, Maryland study: IXA+BEV effective for patients with advanced ovarian cancer

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

The FY24 Defense Appropriations Act is anticipated to provide funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.

April 05, 2024

Vol.50 No.14

In Brief

Roy Herbst elected to Friends board of directors

Roy S. Herbst, deputy director of Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at Yale School of Medicine, was elected to the Friends of Cancer Research Board of Directors.

January 12, 2024

Vol.50 No.02

In the Archives

Yale’s Richard Edelson on what got him started in research for cutaneous T-cell lymphoma

Richard Edelson began his career at NCI, where he was training to become a cancer immunologist.

October 27, 2023

Vol.49 No.40

In Brief

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

Shelley Tworoger, an epidemiologist at Moffitt Cancer Center, was named to two roles at OHSU: head of the Division of Oncological Sciences in the School of Medicine, and associate director for population science at the Knight Cancer Institute.

October 27, 2023

Vol.49 No.40

Drugs & Targets

CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval a Type II variation for Rubraca (rucaparib), as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.

October 20, 2023

Vol.49 No.39

Clinical Roundup

USC researchers develop blood test with the potential to detect early-stage ovarian cancer

A study on human tissue and plasma led by researchers at USC Norris Comprehensive Cancer Center shows that their newly developed blood test, OvaPrint, may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.

October 13, 2023

Vol.49 No.38

Yale, Maryland study: IXA+BEV effective for patients with advanced ovarian cancer

YOU MAY BE INTERESTED IN

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

Roy Herbst elected to Friends board of directors

Yale’s Richard Edelson on what got him started in research for cutaneous T-cell lymphoma

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer

USC researchers develop blood test with the potential to detect early-stage ovarian cancer

Renew today!

Subscriber content

Login